新しいクリーブランドクリニックの研究は、リンパ腫および白血病に対してFDAが承認したイブルチニブ（イブルチニブ）が、最も一般的で致命的な脳腫瘍の治療にも役立つ可能性があり、いつか神経膠芽腫患者にも使用され、生存率を向上させる可能性があることを初めて示した。
米国脳腫瘍協会の報告書によると、膠芽腫の生存率は非常に低く、標準治療を受けた患者の生存期間中央値は 15 か月未満です。 膠芽腫は最も致死率の高い原発性脳腫瘍であり、現在の治療法に対して非常に耐性があります。 これらの患者にできるだけ早く新しい治療法を提供することが急務となっています。
In an earlier study, Bao and colleagues found that 神経膠腫 stem cells contained high levels of a protein called BMX (bone marrow and X-linked non-receptor tyrosine kinase). BMX activates a protein called STAT3 (signal transduction and transcription activator 3), which is responsible for the invasive and tumorigenic properties of glioma stem cells. In this new study, the researchers found that ibrutinib works by inhibiting two proteins.
A research team led by Dr. Shideng Bao of the Cleveland Clinic Lerner Institute found that ibrutinib slowed the growth of brain 腫瘍 in a preclinical model and prolonged survival by more than 10 times that of existing standard chemotherapy drugs. Studies have found that ibrutinib works by inhibiting glioma stem cells, an aggressive brain cancer cell that tends to resist treatment and spread. In addition, combining ibrutinib with radiation therapy can prevent glioblastoma cells from developing drug resistance. Combination therapy is more effective than radiotherapy or ibrutinib alone in overcoming drug resistance and extending lifespan. Follow-up clinical trials are being carried out intensively, and we look forward to receiving FDA approval as soon as possible.
https://medicalxpress.com/news/2018-05-leukemia-lymphoma-drug-benefit-glioblastoma.html
